R2 signs licensing agreement
The University of Chicago is collaborating with R2 Technology on the development of a computer-aided detection mammography workstation, leveraging an investigational CAD reference library that contains a database of both malignant and benign lesions. The
The University of Chicago is collaborating with R2 Technology on the development of a computer-aided detection mammography workstation, leveraging an investigational CAD reference library that contains a database of both malignant and benign lesions. The reference library, which radiologists will be able to access for clinical comparison and relevancy, is being made available to R2 under an exclusive licensing agreement with the University of Chicago. This agreement is a natural extension of R2's existing collaboration with the university. The library may be the means for developing the next generation of CAD tools, according to Michael Klein, president and CEO of R2 Technology. The reference library workstation is designed to display and compare lesions the way most radiologists do in their own minds.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
